'We are still without peers in biosimilars'
Biocon clocked 10% revenue growth in the Covid-hit M9FY21. In an interview with FE's Srinath Srinivasan, Kiran Mazumdar Shaw, executive chairperson, highlights the reasons for her confidence in the biosimilar business. Edited excerpts:.
from Google Alert - Business https://ift.tt/30spifN
Biocon clocked 10% revenue growth in the Covid-hit M9FY21. In an interview with FE's Srinath Srinivasan, Kiran Mazumdar Shaw, executive chairperson, highlights the reasons for her confidence in the biosimilar business. Edited excerpts:. https://ift.tt/eA8V8J
from Google Alert - Business https://ift.tt/30spifN
Biocon clocked 10% revenue growth in the Covid-hit M9FY21. In an interview with FE's Srinath Srinivasan, Kiran Mazumdar Shaw, executive chairperson, highlights the reasons for her confidence in the biosimilar business. Edited excerpts:. https://ift.tt/eA8V8J
Comments
Post a Comment